Physician profile
Narinder Kaur
NPI 1508072224
$1,179.65
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.74 · 2022: $414 · 2023: $462 · 2024: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $233.76 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.53 | 2023-2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $124.99 | 2022 | |
| Amgen INC. | $124.99 | 2023 | Repatha |
| Novo Nordisk INC | $117.05 | 2022 | |
| Lilly USA, LLC | $111.73 | 2023 | Mounjaro |
| Glaxosmithkline, LLC. | $105.84 | 2024 | Arexvy |
| Electromed, INC. | $51.41 | 2024 | Smartvest |
| Boston Scientific Corporation | $35.33 | 2023-2024 | Lux-Dx Insertable Cardiac Monitor |
| Janssen Pharmaceuticals, INC | $28.50 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $18.78 | 2022 | |
| Becton, Dickinson and Company | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narinder Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.